{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:03:54Z","timestamp":1761541434694},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japanese Society of Lacrimal Passage and Tear Dynamics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10384-018-0603-8","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T09:43:23Z","timestamp":1529574203000},"page":"432-437","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1"],"prefix":"10.1007","volume":"62","author":[{"given":"Yoko","family":"Akune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Shigeyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"603_CR1","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"603_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CAD.0b013e3283440231","volume":"22","author":"O Nishiyama","year":"2011","unstructured":"Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, et al. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. Anticancer Drugs. 2011;22:811\u20136.","journal-title":"Anticancer Drugs"},{"key":"603_CR3","doi-asserted-by":"publisher","first-page":"e0116965","DOI":"10.1371\/journal.pone.0116965","volume":"10","author":"K Tsukahara","year":"2015","unstructured":"Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T, et al. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One. 2015;10:e0116965.","journal-title":"PLoS One"},{"key":"603_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000;83:141\u20135.","journal-title":"Br J Cancer"},{"key":"603_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/BF02968301","volume":"11","author":"T Saeki","year":"2004","unstructured":"Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer\u2014a Japanese trial by the S-1 Cooperative Study Group. Breast Cancer Working Group. Breast Cancer. 2004;11:194\u2013202.","journal-title":"Breast Cancer"},{"key":"603_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"603_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849\u201355.","journal-title":"Cancer Chemother Pharmacol"},{"key":"603_CR8","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000\u20135.","journal-title":"Clin Cancer Res"},{"key":"603_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jjco\/hyn127","volume":"39","author":"T Shirasaka","year":"2009","unstructured":"Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2\u201315.","journal-title":"Jpn J Clin Oncol."},{"key":"603_CR10","first-page":"487","volume":"4","author":"Y Miao","year":"2015","unstructured":"Miao Y, Zhan P, Lv T, Song Y. A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients. Transl Lung Cancer Res. 2015;4:487\u201397.","journal-title":"Transl Lung Cancer Res"},{"key":"603_CR11","first-page":"2896","volume":"15","author":"T Chikama","year":"2009","unstructured":"Chikama T, Takahashi N, Wakuta M, Nishida T. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis. 2009;15:2896\u2013904.","journal-title":"Mol Vis"},{"key":"603_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10384-010-0917-7","volume":"55","author":"H Kobashi","year":"2011","unstructured":"Kobashi H, Kamiya K, Shimizu K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol. 2011;55:163\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"603_CR13","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/OPX.0000000000000543","volume":"92","author":"KH Kim","year":"2015","unstructured":"Kim KH, Kim WS. Corneal limbal stem cell deficiency associated with the anticancer drug s-1. Optom Vis Sci. 2015;92:S10\u20133.","journal-title":"Optom Vis Sci"},{"key":"603_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ajo.2005.01.052","volume":"140","author":"B Esmaeli","year":"2005","unstructured":"Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140:325\u20137.","journal-title":"Am J Ophthalmol"},{"key":"603_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10384-012-0127-6","volume":"56","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, Miyashita H, Miyanaga T, Yamamoto K, Sugiyama K. Dacryoendoscopic observation and incidence of canalicular obstruction\/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012;56:214\u20138.","journal-title":"Jpn J Ophthalmol."},{"key":"603_CR16","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/annonc\/mds106","volume":"23","author":"N Kim","year":"2012","unstructured":"Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065\u201371.","journal-title":"Ann Oncol"},{"issue":"1275","key":"603_CR17","first-page":"e4","volume":"117","author":"Y Matsumoto","year":"2010","unstructured":"Matsumoto Y, Dogru M, Sato EA, Ibrahim OM, Tatematsu Y, Ogawa Y, et al. S-1 induces meibomian gland dysfunction. Ophthalmology. 2010;117(1275):e4\u20137.","journal-title":"Ophthalmology"},{"key":"603_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12885-015-1781-0","volume":"15","author":"S Mizoguchi","year":"2015","unstructured":"Mizoguchi S, Okada Y, Kokado M, Saika S. Abnormalities in the meibomian glands in patients with oral administration of anticancer combination drug-capsule TS-1((R)): a case report. BMC Cancer. 2015;15:796.","journal-title":"BMC Cancer"},{"key":"603_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10384-008-0536-8","volume":"62","author":"H Sakamoto","year":"2008","unstructured":"Sakamoto H, Sakamoto M, Hamada T, Kubota T, Ishibashi T. A case of corneal lesion following treatment by peroras TS-1. Jpn J Clin Ophthalmol. 2008;62:393\u20138.","journal-title":"Jpn J Clin Ophthalmol"},{"key":"603_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00007691-200304000-00013","volume":"25","author":"L Zufia","year":"2003","unstructured":"Zufia L, Aldaz A, Castellanos C, Giraldez J. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Ther Drug Monit. 2003;25:221\u20138.","journal-title":"Ther Drug Monit"},{"key":"603_CR21","first-page":"513","volume":"10","author":"MA Nassim","year":"2002","unstructured":"Nassim MA, Shirazi FH, Cripps CM, Veerasinghan S, Molepo MJ, Obrocea M, et al. An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med. 2002;10:513\u20136.","journal-title":"Int J Mol Med"},{"key":"603_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/bmc.2741","volume":"27","author":"B Buchel","year":"2013","unstructured":"Buchel B, Rhyn P, Schurch S, Buhr C, Amstutz U, Largiader CR. LC-MS\/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr. 2013;27:7\u201316.","journal-title":"Biomed Chromatogr"},{"key":"603_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","volume":"31","author":"JH Beumer","year":"2009","unstructured":"Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit. 2009;31:688\u201394.","journal-title":"Ther Drug Monit"},{"key":"603_CR24","first-page":"29","volume-title":"Fluoropyrimidines in cancer therapy","author":"G Milano","year":"2003","unstructured":"Milano G. Dihydropyrimidine dehydrogenase and treatment by fluoropyrimidines-past and future directions. In: Rustum Y, editor. Fluoropyrimidines in cancer therapy. New Jersey: Humana Press; 2003. p. 29\u201336."},{"key":"603_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00004397-200010000-00009","volume":"40","author":"K Tsubota","year":"2000","unstructured":"Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113\u201322.","journal-title":"Int Ophthalmol Clin."},{"key":"603_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/prca.200700125","volume":"1","author":"K Wu","year":"2007","unstructured":"Wu K, Zhang Y. Clinical application of tear proteomics: present and future prospects. Proteom Clin Appl. 2007;1:972\u201382.","journal-title":"Proteom Clin Appl"},{"key":"603_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1021\/jp994432b","volume":"105","author":"YH Jang","year":"2001","unstructured":"Jang YH, Sowers LC, Cagin T, Goddard WA 3rd. First principles calculation of pKa values for 5-substituted uracils. J Phys Chem A. 2001;105:274\u201380.","journal-title":"J Phys Chem A."},{"key":"603_CR28","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/molecules13102608","volume":"13","author":"S Farquharson","year":"2008","unstructured":"Farquharson S, Gift A, Shende C, Inscore F, Ordway B, Farquharson C, et al. Surface-enhanced Raman spectral measurements of 5-fluorouracil in saliva. Molecules. 2008;13:2608\u201327.","journal-title":"Molecules"},{"key":"603_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/bioinformatics\/btu637","volume":"31","author":"E Bunkute","year":"2015","unstructured":"Bunkute E, Cummins C, Crofts FJ, Bunce G, Nabney IT, Flower DR. PIP-DB: the protein isoelectric point database. Bioinformatics. 2015;31:295\u20136.","journal-title":"Bioinformatics"},{"key":"603_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1445-5994.1979.tb04317.x","volume":"9","author":"N Christophidis","year":"1979","unstructured":"Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9:143\u20134.","journal-title":"Aust N Z J Med"},{"key":"603_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1081\/CUS-120015900","volume":"21","author":"A Huhtala","year":"2002","unstructured":"Huhtala A, T\u04d3hti H, Salminen L, Uusitalo H. Evaluation of adverse ocular effects of 5-fluorouracil by using human corneal epithelial cell cultures. J Toxicol Cutan Ocular Toxicol. 2002;21:283\u201392.","journal-title":"J Toxicol Cutan Ocular Toxicol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-018-0603-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T23:20:29Z","timestamp":1561072829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-018-0603-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s10384-018-0603-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"29 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y Akune, None; M. Yamada, None; C. Shigeyasu, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}